SAN DIEGO, CA – (August 1, 2016) - Diazyme Laboratories today announced that it has purchased substantially all of the assets of Diadexus, Inc. (Diadexus), including all intellectual property. Diazyme is excited to now offer the Diadexus PLAC® assays.
"Adding the PLAC assays to Diazyme’s already comprehensive diagnostic testing for heart disease demonstrates Diazyme’s commitment to providing complete clinical diagnostic solutions to doctors and patients” said Dr. Chong Yuan, Managing Director of Diazyme Laboratories. “The PLAC Test ELISA Kit is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. The PLAC test for Lp-PLA2 Activity is the only FDA approved test for risk prediction of CHD in patients with no prior history of cardiovascular events. The PLAC assays are recommended to be used as an adjunct to traditional risk factor assessment to identify moderate and high-risk individuals who may actually be at an increased risk for heart attack or stroke.”
Diazyme Laboratories is a division of General Atomics headquartered in La Jolla, California. Diazyme uses its enzyme and antibody platform technologies to develop innovative assays for clinical and research uses with reduced costs and improved performance. Products include diagnostic blood tests for cardiovascular disease, diabetes, nutritional assessment, liver disease, renal disease and electrolytes. Information regarding Diazyme's enzyme technology and related products can be found on its website at www.diazyme.com.
For Further Information Contact:
Dr. Abhijit Datta, Ph.D
Posted on Mon, August 1, 2016